


## PHARMACEUTICAL 2017

Bristol Myers Squibb

## BRISTOL MYERS SQUIBB CO Rank 28 of 313





RealRate

## PHARMACEUTICAL 2017

Bristol Myers Squibb

## BRISTOL MYERS SQUIBB CO Rank 28 of 313

The relative strengths and weaknesses of BRISTOL MYERS SQUIBB CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BRISTOL MYERS SQUIBB CO compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 385% points. The greatest weakness of BRISTOL MYERS SQUIBB CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 558% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	13,704,000
Cost of Goods Sold	0
Intangible Assets	8,260,000
Liabilities, Current	8,841,000
Liabilities, Non-Current	6,999,000
Other Assets	6,763,000
Other Compr. Net Income	-85,000
Other Expenses	5,069,000
Other Liabilities	1,520,000
Other Net Income	0
Property and Equipment	4,980,000
Research and Development	4,940,000
Revenues	19,427,000
Selling, General and Administrative Expense	4,911,000

Output Variable	Value in 1000 USD
Assets	33,707,000
Liabilities	17,360,000
Expenses	14,920,000
Stockholders Equity	16,347,000
Net Income	4,507,000
Comprehensive Net Income	4,464,500
Economic Capital Ratio	141%

